newsfilter.io

Drug Manufacturers - General — industry outlook

  • Period: 2026-10-19 to 2026-11-09
  • Events: 3
  • Generated: 2026-11-09T07:30:00.003Z

Financial Guidance and Revenue Trajectory

Bristol Myers Squibb (BMY) raised its 2026 Non-GAAP EPS guidance to $6.35–$6.55 and expects 2026 Legacy Portfolio Revenue to decline 3%–5%; Eli Lilly (LLY) raised its 2026 Full-Year Revenue to $91–$92 billion and revised its Non-GAAP EPS projection to $35–$36. BMY anticipates a $1.5–$2 billion revenue step-down in 2027 primarily driven by U.S. LOE, whereas LLY projects modest mix shifts toward lower net prices in 2027 due to expanded Medicare coverage, though it expects sustained volume growth in the incretin market. BMY maintains a gross margin of 68.4%, while LLY revised its Non-GAAP performance margin to 52%–52.5%.

Incretin Market Expansion and Pricing Dynamics

Eli Lilly (LLY) highlighted that U.S. incretin prescriptions grew 82% in Q3 2026, with Fondeo capturing ~45% of new oral GLP-1 growth and the Medicare GLP-1 Bridge Program generating an estimated $20 billion in cumulative savings over 10 years; the company anticipates permanent Part D benefit expansion by 2028. BMY (BMY) reports Eliquis growth driven by net price increases and expects $1.5–$2 billion in revenue decline in 2027 due to European patent expiration. LLY projects Fondeo regulatory review for Type 2 diabetes in the U.S. in Q4 2026, with global rollout in 2027, while BMY expects Eliquis growth to remain 20%–25% for 2026 despite U.S. growth offset by European LOE.

Pipeline Progression and Clinical Milestones

Bristol Myers Squibb (BMY) targets $1.5–$2 billion in revenue from Cuvantic by end of launch with 30%–40% conversion from Opdivo IV, anticipates Admilpirant PPF Phase 3 results in Q1 2027, and expects Milvexian Secondary Stroke Prevention data before year-end 2026. Eli Lilly (LLY) plans Fondeo launches in Type 2 diabetes in Q4 2026, global Fondeo launches in 2027, and expects Ember-4 to read out in 2027; LLY also notes Retatrutide showed 20-21% weight loss in Phase 3 and Elora-TZP showed 23.3% weight loss in Phase 2. BMY (BMY) anticipates Mezignamide PDUFA in May 2027, SOTIC2 Lupus readouts before year-end 2026, and Glucotamide registrational data in 2027, while LLY (LLY) submitted Leverkizumab data for hand/foot atopic dermatitis and advanced Mer-511 in Phase 1.

Manufacturing Capacity and Strategic Capital Allocation

Bristol Myers Squibb (BMY) announced a $2.3 billion manufacturing investment in Houston and a $170 million investment in Indiana for a radiopharmaceutical facility by end of 2029, targeting $2 billion in efficiency savings by end of 2027. Eli Lilly (LLY) broke ground on $6.5 billion and $5 billion facilities in Houston and Richmond, VA, respectively, to support long-term capacity. BMY (BMY) holds $13 billion in cash equivalents and targets AI-driven 20–30% reduction in drug testing timelines, while LLY (LLY) acquired Atai-Beckley and Merida Biosciences and committed to providing obesity treatment in resource-limited settings by 2040.

Therapeutic Portfolio Diversification

Bristol Myers Squibb (BMY) reports its Growth Portfolio includes eight medicines annualizing over $1 billion, with Cuvantic annualizing over $1.3 billion and Reblozyl up 22%; LLY (LLY) focuses on three non-obesity pillars (Oncology, Neuroscience, Immunology) with eight new oncology medicines in Phase 3 or nearing start. BMY (BMY) expects ZemBexis to become a foundational multiple myeloma therapy alongside Mezignamide and anticipates Neuroscience growth in Alzheimer's Disease Psychosis among 7 million patients. LLY (LLY) sees Kisunla driving growth via diagnostic testing and expects oral obesity medicines to expand the total addressable market rather than cannibalize injectables, noting Zepbound persistency will match historical Trulicity benchmarks of 16–18 months.

Operational Risks and Regulatory Uncertainty

Bristol Myers Squibb (BMY) faces headwinds from a paused ZolaCell program following a fatal sepsis/pneumonia case, 120mg dose results failure for Admilpirant in IPF, and inventory drawdowns affecting Chemzios and CoBenfi; LLY (LLY) cites execution variability on the Medicare Bridge Program, potential net price declines in the U.S. due to government mix shifts, and clinical uncertainty surrounding Ember-4 and triple agonist trials. BMY (BMY) notes competitive pressure on Opdivo and SCLC data requirements, while LLY (LLY) highlights supply chain constraints mitigated by new capacity and adherence risks where oral formulations may show lower persistence than injectables.